Logotype for MedCap

MedCap (MCAP) Q4 14/15 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for MedCap

Q4 14/15 earnings summary

13 Nov, 2026

Executive summary

  • FY2014/15 revenue grew to SEK 852.8m from SEK 826.1m, while net profit fell to SEK 9.5m from SEK 26.3m amid weaker profitability at Abilia and Unimedic and restructuring activity.

  • Positive operating cash flow, a SEK 50m directed share issue and lower borrowings strengthened the financial position; focus remained on developing existing holdings and pursuing disciplined add-on acquisitions.

Financial highlights

  • Revenue was SEK 852.754m versus SEK 826.086m; operating profit was SEK 10.940m versus SEK 30.888m; profit after tax was SEK 9.458m versus SEK 26.258m.

  • Adjusted EBITDA was SEK 31.034m versus SEK 55.412m; adjusted EBITDA excludes depreciation and amortization and segment management fees as described in segment reporting.

  • Operating cash flow was SEK 2.258m versus SEK 0.865m; year-end cash was SEK 75.341m versus SEK 21.222m, and borrowings were SEK 141.536m versus SEK 191.630m.

  • A SEK 50m directed share issue was completed in May 2014; the year-end share price was SEK 2.76 versus SEK 4.25, with FY share performance of -33% versus +9% for the First North All-Share index.

Outlook and guidance

  • Specialty Pharma was expected to remain the primary growth engine, supported by further proprietary product registrations and Nordic licensing agreements.

  • Unimedic planned continued CDMO efficiency measures and a streamlined Pharma Trading operation; new CDMO products were expected to begin selling in FY2015/16.

  • Abilia aimed to build on UK growth, integrate operations and pursue international distribution, while Quickels planned new product launches and expansion into additional markets.

  • Acquisition capacity was estimated at just over SEK 50m in equity, or approximately SEK 100m including expected debt financing; investment discipline remained a priority despite high acquisition prices.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from MedCap